Drug Profile
Research programme: tapentadol - Ensysce Biosciences
Alternative Names: PF 16; Tapentadol Bio-MD™ SystemLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator PharmacoFore
- Developer Ensysce Biosciences
- Class Amines; Opioid analgesics; Phenols; Small molecules
- Mechanism of Action Alpha 2 adrenergic receptor antagonists; Opioid mu receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Discontinued Pain
Most Recent Events
- 24 Feb 2016 Discontinued for Pain in USA (PO)
- 19 Jan 2016 Signature Therapeutics merged into Ensysce Biosciences
- 03 Sep 2012 Research programme: tapentadol - Signature Therapeutics is available for licensing as of 03 Sep 2012. www.ensysce.com